Hot Takes: What the Oral Arguments in Hikma/ Amarin Revealed

The Supreme Court heard oral arguments yesterday in Hikma Pharmaceuticals USA v. Amarin Pharma, Inc., a case with broad implications for the generic industry’s practice of “skinny labeling” and the induced infringement standard for patent law and beyond. The Justices during yesterday’s oral argument seemed skeptical of creating new rules or standards for inducement and expressed concern about potential harm to the generic pharmaceutical industry as a result of the U.S. Court of Appeals for the Federal Circuit’s 2024 precedential decision.

IPWatchdog reached out to members of the IP community for their initial takeaways from yesterday’s arguments. From exposing flaws in the Hatch-Waxman Act’s intended balance to suggesting the Court might simply reinforce the proper application of rule 12(b)(6), here is what our commenters had to say about the Justices’ line of questioning.

Jeffrey Depp, The Committee for Justice 

“The oral argument in Hikma v. Amarin inadvertently exposed a deeper flaw—not just in inducement doctrine, but in the entire Hatch-Waxman framework. What we are witnessing is the inevitable unraveling of a system built on what Austrian economist F.A. Hayek famously called the “fatal conceit”: the belief that policymakers can engineer complex markets from the top down.

Hatch-Waxman rests on precisely that conceit. It assumes regulators can finely calibrate incentives—accelerating generic entry while preserving innovation—through devices like “skinny labels.” But as the argument made clear, real-world behavior refuses to cooperate with this design. When the government suggested Hikma’s product is essentially “the same stuff,” it underscored a reality anyone familiar with pharmaceutical markets understands: doctors and patients do not parse labels with legalistic precision. They are far more practical, responding to price, access, and therapeutic substitutability.

That reality collides directly with inducement doctrine. The Federal Circuit treated this as a fact-bound inquiry into how Hikma’s statements might be interpreted in the marketplace. But the deeper truth is more fundamental: the entire “skinny label” construct is largely irrelevant to how drugs are actually prescribed. Physicians are not bound by labels, and patients—facing real economic constraints—are even less so. Labels are artifacts of regulatory design, not drivers of medical decision-making.

Meanwhile, defenders of the status quo invoke Hatch-Waxman’s supposed “balance” between innovation and access. But after four decades, that balance looks increasingly illusory. We still face high drug prices, alongside mounting evidence that the regime dampens incentives for developing new indications and breakthrough therapies.

From an Austrian perspective (see above), this is predictable. Innovation is a discovery process, not a variable to be optimized by statute. By privileging early generic entry, Hatch-Waxman shrinks the expected returns that fuel that process—reducing the very pool of future drugs that would eventually become generic.

The Court should resist limiting inducement liability in ways that double down on this flawed system. The real lesson of Hikma is not how to refine Hatch-Waxman—but why its underlying premises deserve far more skepticism.”

Chad Landmon, Polsinelli

“Although it’s always difficult to predict the outcome based on oral argument, the questions from the Justices (and the responses from the parties) suggested that a new standard for induced infringement is unlikely to be adopted. Instead, it appears that SCOTUS might apply the traditional standards for induced infringement, which requires active encouragement, to the facts of the case.

The procedural posture of the case (a motion to dismiss) has led to some speculation that the Justices may only rule on the procedural issues relating to the pleadings standards, which appears to be the direction that Justice Coney Barrett may be inclined to follow. But the overall questioning relating to inducement standards suggests that SCOTUS may be interested in weighing in on the patent merits surrounding skinny labeling, albeit likely without adopting any new legal framework.

At least some members of the Court expressed interest on the broader policy impacts of the Federal Circuit’s decision on the generic pharmaceutical market and cost of drugs, with Justice Gorsuch even citing the amicus brief from Henry Waxman (yes, the Waxman responsible for the Hatch-Waxman Act!), which suggested that affirming the Federal Circuit would “gut” the Hatch-Waxman balance. It will be interesting to see how much the policy issues surrounding drug affordability and the ultimate goals of the Hatch-Waxman Act come into play in the decision.

A ruling for Hikma may reduce uncertainty for generic and biosimilar companies utilizing skinny labels, potentially exempting them from being held liable for induced infringement as long as they properly carve a covered indication from their label.

A ruling for Amarin would likely lead to increased litigation against generic pharmaceutical companies that utilize skinny labels, creating more uncertainty when such companies launch their products on the market.”

Will Milliken, Sterne Kessler

“Those hoping Hikma would produce a detailed gloss on the standard for inducement in the skinny label context—or even the standard for inducement generally—may be disappointed. Several Justices’ questions suggested that they view the case as presenting a straightforward question about the application of the established Twombly/Iqbal “plausibility” pleading standard to a particular set of facts. So, the Court may decline to resolve broader questions about how the skinny label regime should work and instead simply give us another example of how to properly apply Rule 12(b)(6).”

Erick Palmer, Honigman LLP

“Under ordinary circumstances, the Court would not have granted certiorari in this case because the proper standard was not disputed: everyone agreed this is an inducement case subject to the plausibility pleading standard of Twombly/Iqbal. But the Petitioner and Government convinced the Court this case has broad policy implications that would “gut” Congress’ approval of Section (viii) carve-outs and impede the public’s access to generic drugs—contentions directly undermined by the fact that seven other companies are lawfully marketing the same generic drug under skinny labels.

Although several Justices cautioned against developing categorical rules for skinny label cases, others suggested at the urging of the Government that statutory labeling requirements should isolate statements in drug labels from being used to show active inducement. Still others suggested press releases directed primarily to investors should not be used to show intent to induce doctors to infringe. If the majority adopts these suggestions, they could impact how FDA-approved product labels and press releases are used to prove inducement in pharmaceutical cases generally, not just in skinny label cases. They may also require more detailed factual allegations regarding intent—including facts that may be solely in the possession of the generic company prior to discovery.

Given these far-reaching consequences, practitioners in the pharmaceutical arts like me will be waiting anxiously—or eagerly, depending on which side you are on—for the Court’s guidance in its forthcoming decision.”

David Rosen, Foley & Lardner

“Amarin is not challenging the statutory provision providing for skinny labeling.  Numerous companies have approved ANDAs for Icosapent ethyl that Amarin has not sued. In this case, Amarin is seeking the opportunity to overcome Hikma’s summary judgement motion that would allow Amarin to challenge whether or not Hikma’s advertising and promotional statements and practices around its approved ANDA for Icosapent ethyl is inducing infringement of Amarin’s patents covering reducing the risk of cardiovascular events with Vascepa.

The question is whether Hikma’s advertising and promotional statements and practices is actively or passively inducing infringement of Amarin’s patents. Apparently, Hikma has stated that its product is a generic version Vascepa and is rated as therapeutically equivalent (“AB rated”) in FDA’s Approved Drug Product’s List with Therapeutic Equivalence Evaluations (“the FDA’s Orange Book”). Both are true statements.

This case is very important to the generic pharmaceutical industry and to the public, as generics are much less expensive than brand products. If advertising and promotional statements are determined to be judged under a passive inducement standard, this will have a chilling effect on generic companies seeking to obtain FDA approval by carving out for uses of a drug that are protected by periods of patent and/or market exclusivity since they could be subject to expensive litigation and potential significant damages. Generic companies are likely to review advertising and promotional statements as well as market projections to ensure that they do not suggest uses covered by carved out patents or market exclusivity.”